

Hemoadsorption Combined with Hemodialysis and the "Inflammation Mitigation Hypothesis"

Alessandra Brendolan¹, Anna Lorenzin¹, Massimo De Cal¹, Grazia Maria Virzi¹, Vincenzo Cantaluppi², Marita Marengo³, Paolo Lentini⁴, Claudio Ronco¹

ABSTRACT

Clinical outcomes are still unsatisfactory in patients undergoing chronic maintenance dialysis. Signs and symptoms of uremic intoxication are often present even in presence of an adequate dialysis delivery. These along with cardiovascular and skeletal complications, have been correlated to the accumulation of inflammatory chemical mediators, beta-2 microglobulin (β 2M), parathyroid hormone (PTH) and other middle to large molecular weight toxins that are insufficiently cleared by current dialysis techniques. Such condition determines a vicious loop where a subclinical status of inflammation causes a disruption of the immunological response affecting outcomes by accelerated atherosclerosis, anemia, and frequent infections. The overall picture can be described as a systemic inflammatory syndrome with simultaneous activation of the innate and the adaptive immunity. In such condition, new options and techniques are required to achieve a more effective blood purification and to correct the altered immuno-homeostasis. New efficient and biocompatible sorbents are today available (HA 130 Cartridge, Jaftron Medical, Zhuhai, China) and they can be advantageously coupled in series with the hemodialyzer to perform hemoadsorption combined with hemodialysis (HA-HD). This technique has been already studied in at least two randomized trials demonstrating an effective improvement of clinical and biochemical outcomes. We have calculated the kinetics of β 2M in a single session, in a series of three consecutive sessions of a week and in a period of three months using different frequencies of application (first month: Three sessions per week; second month: Two sessions per week; third month: One session per week). In the single session the reduction ratio was superior to other techniques such as hemodialysis (HD), high-flux hemodialysis (HFD) or hemodiafiltration (HDF). In the thrice weekly regime, the time average concentration (TAC) of β 2M resulted inferior to HD and HDF. In the long period, a lower concentration of β 2M was maintained even with a once-a-week regime. Considering the parallel reduction of inflammatory parameters, we could hypothesize that the enhanced removal of uremic toxins and chemical mediators led to a mitigation of the systemic inflammation with a progressive reduction in the generation of β 2M. This "inflammation mitigation hypothesis (IMH)" supports the prescription of HA-HD once a week, possibly after a month of thrice weekly regime.

Key words: Hemoadsorption, sorbents, hemodialysis, inflammation, uremia, cytokines

INTRODUCTION

In the setting of intensive care, patients with sepsis or acute kidney

injury (AKI) often present a clinical picture of dysregulated immunological response syndrome.^[1-3] When this response is uncontrolled, a typical cytokine release syndrome (CRS) may occur, and patients experience endothelial dysfunction, hemodynamic instability and multiple organ failure. CRS can be caused by bacteria, virus or other stimuli that induce a significant activation of innate and adaptive immunity and, consequently, an uncontrolled inflammatory response.^[4-7] This picture is common in sepsis where it is characterized by a cascade of events that includes endotoxin uptake by CD14 receptors in the monocytes and subsequent release mediators (cytokines) into the systemic circulation, major biological effects including vaso-permeabilization, hypotension and shock, with significant clinical consequences.^[8]

In end-stage renal disease (ESRD) patients are stable but they may still suffer from a condition of chronic or subclinical inflammation leading to cardiovascular complications, progressive malnutrition, and death.^[9] In these patients, the phenomenon is due to uremia retention molecules not adequately cleared by current dialysis techniques and a state of smoldering inflammation with increased concentrations of middle-to-large molecular species including cytokines, acute phase proteins, light chains and others.^[10-13]

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

¹International Renal Research Institute of Vicenza and Department of Medicine, University of Padova, San Bortolo Hospital Vicenza, Vicenza 36100, Italy. ²Nephrology and Kidney Transplantation Unit, Department of Translational Medicine, University of Piemonte Orientale (UPO), Via Solaroli 17, Novara 28100 Italy. ³Nephrology and Dialysis Unit, ASL CN1, Via Boggio 12, Cuneo 12100, Italy. ⁴UOC Nefrologia, ospedale San Bassiano, Via dei Lotti 40, Bassano del Grappa 36061, Italy

***Address for correspondence:** International Renal Research Institute of Vicenza and Department of Medicine, University of Padova, San Bortolo Hospital, Viale Rodolfi 37, Vicenza 36100, Italy. E-mail: cronco@goldnet.it; <https://orcid.org/0000-0002-6697-4065>

Copyright © 2024 The Authors. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Integr Med Nephrol Androl 2024;11:e00006

Received: 16 January 2024; **Accepted:** 31 January 2024

<https://doi.org/10.1097/IMNA-D-24-00006>

There are several reasons why hemodialysis patients are subject to chronic inflammation. The condition of uremia per se is characterized by a series of metabolic disturbances that produce an imbalance between immune-stimulation and immune-depression. There is a disequilibrium between production of reactive oxygen species (ROS) and antioxidant defense of the organism. Furthermore, the hemodialysis technique can be responsible of an inflammatory condition due to possible contamination of the hemodialysis fluid, membrane bio-incompatibility and extracorporeal shear stress on blood cells. This may also be exacerbated by other patient-related factors such as infections, periodontal disease, and atherosclerosis [Table 1].

Despite recent improvements in dialysis technology, cardiovascular disease still remains the main cause of morbidity and mortality in ESRD. Traditional risk factors include hypertension, chronic heart failure, dyslipidemia, obesity, tobacco smoking and diabetes. Further risks, however, have recently been shown to be involved including chronic inflammation, oxidative stress, advanced glycosylation end products (AGEs) formation, malnutrition, Ca-P product, endothelial dysfunction and hyper-homocysteinemia.^[9,14]

All these risks factors combine their action to produce medium to long-term clinical complications and unsatisfactory outcome. In particular, the retention of uremic toxins in the middle-to-high molecular range and the concomitant activation of the inflammatory cascade may result in further activation of cytokines, acute phase reactants (C-reactive protein [CRP], fibrinogen, serum amyloid A [SAA], transferrin) and damage-associated molecular patterns (DAMPs) causing a cascade of events including endothelial dysfunction, accelerated atherogenesis and cardiovascular complication.^[15]

Mortality, morbidity, and hospitalization positively correlate with specific compounds (CRP, SAA, parathyroid hormone [PTH] and beta-2 microglobulin [β 2M]) and with cytokines that regulate their metabolism (such as interleukin-6 [IL-6]).^[16] β 2M and PTH seem to be activated by the inflammatory process, but they could also be active participants in the process. Stevinkel *et al.*^[17] have demonstrated significantly different outcomes in patients with CRP above or below 10 mg/L. Kayesen *et al.*^[18] have also demonstrated that longitudinal variations in albumin concentration correlate with CRP levels, suggesting that malnutrition is a condition induced by chronic inflammation. In conclusion, ESRD patients are at risk for cardiovascular disease and early atherosclerotic lesions seem to contribute to negative outcomes. In conclusion, a chronic status of inflammation, although often subclinical, has been demonstrated in patients undergoing chronic hemodialysis. Several factors [Table 1] may mediate biochemical and physical processes that activate an inflammatory response in the patient, and subsequently influence outcomes.

In physiological conditions, pro and anti-inflammatory mediators are in a continuous equilibrium. In critically ill patients with sepsis, the overproduction of mediators generates systemic effects including endothelial damage, hemodynamic shock, and vaso-paralysis. At the same time, monocytes present a profound depression of their capacity to respond to different stimuli up to a complete immuno-paralysis.^[19] In ESRD, the chronic presence of uremic toxins disrupts the immunological homeostatic balance in a less acute, but still insidious mode.

Table 1**Chronic inflammation in maintenance hemodialysis.**

Patient-related and/or endogenous causes	Treatment-related issues
Age, gender and race	Repeated vascular access puncture
Decreased endogenous cytokine clearance	Indwelling temporary catheters
Reduced metabolism of AGEs	Presence of prosthetic devices
Increased cytokine synthesis	Repeated contact with dialysis membrane and tubing
Gene polymorphism (differences)	Back-transport of pyrogens from dialysate
Chronic heart failure, atherosclerosis	Oxidative and carbonyl stress
Chronic infections or localized infections (catheters)	Type of membrane
Periodontal disease	Type of technique

AGEs, advanced glycosylation end products.

This condition leads to a subclinical battle within the organism in which phases of inflammation are followed by phases of immunodepression and cell hypo-responsiveness.^[20] While the former phases increase cardiovascular abnormalities and malnutrition, the subsequent phases lead to an impaired response to bacterial invasion and easy occurrence of infections. These factors result in subsequent phases of inflammation and immuno-depression while the patient enters a slippery slope of progressive clinical impairment. This process may take several years but it is documented by subsequent episodes of acute inflammation and infections, cardiovascular events and hospitalization, malnutrition, and progressive reduction in body mass. Thus, there is a paradox where a chronic inflammatory state leading to complications and immuno-depression facilitate infection, coexist in patients on dialysis. The clinical effects of these two entities is an increased cardiovascular risk with progressive cardiovascular disease, and a series of infections that periodically stimulate a new inflammatory cycle. There are now several lines of evidence that retention of uremic toxins may affect this process by blockade of enzymatic pathways, altered monocyte function and activation of complex protein pathways.^[21] Such toxins are not effectively removed by current dialysis techniques.^[22] Thus, a more adequate extracorporeal therapy should be prescribed and delivered to mitigate the systemic inflammatory response syndrome-compensatory anti-inflammatory response syndrome (SIRS-CARS) condition through an effective removal of uremia retention molecules insufficiently cleared by the classic dialysis techniques.

THE RATIONALE FOR COMBINING HEMODSORPTION WITH HEMODIALYSIS

Given that most uremia retention toxins and DAMPs are in the molecular weight range of 10 to 50 kDa, current dialysis techniques based on membrane separation processes (relying on diffusion and convection) are unable to effectively remove them.^[22] Although more efficient, techniques have been developed such as hemodiafiltration (HDF) or expanded hemodialysis (HDx),^[23,24] full correction of uremia retention syndrome has not been achieved yet and thus, new therapeutic options are required.

New sorbent materials with enhanced porosity and biocompatibility characteristics have become recently available.^[25] The sorbent is composed by a mixture of styrene and divinylbenzene

with a specific porosity generated during the beads formation. Biocompatible coating ensures adequate hemocompatibility and absence of side effects.^[26] Aspecific adsorption of molecules in the range of 10 to 50 kDa occurs by Van der Waals forces, ionic bonds, and hydrophobic bonds.^[27] These characteristics allow to overcome the limitations imposed by classic and innovative dialysis membranes and permit to reduce the peaks of chemical mediators and middle-to-high molecular weight toxins involved in signs and symptoms of uremic intoxication [Figure 1]. Furthermore, the simultaneous clearance of circulating cytokines both in the pro and anti-inflammatory side, may allow for a re-equilibration of the immuno-homeostasis.^[28] Interesting results have been achieved in randomized controlled trials combining hemoadsorption with hemodialysis (hemoadsorption combined with hemodialysis [HA-HD]).^[29,30] Independently on the hemodialyzer utilized, the sorbent cartridge HA 130 (Jafon Medical, Zhuhai, China) placed in series before the dialysis filter, has demonstrated remarkable efficacy in reducing the levels of β 2M, PTH, Cytokines and other retention molecules with significant improvement of several different symptoms and clinical outcomes [Table 2]. This has led to consider HA-HD as a new option for ESRD patients with symptoms and complications.^[31] Analyzing the results obtained in these papers and in our own experience, on the kinetics of β 2M in a single session, in a series of three consecutive sessions of a week and in the last week of each month for three months using different frequencies of application (first month: Three sessions per week; second month: Two sessions per week; third month: One session per week), and integrating those data with previously achieved results,^[29,30,32–36] we were able to formulate a possible hypothesis on the beneficial effect of combining hemoadsorption with hemodialysis.

THE INFLAMMATION MITIGATION HYPOTHESIS (IMH)

The peak concentration theory published several years ago,^[37–39] despite being conceived in acute illness, may result particularly useful to study new techniques of blood purification (such as hemoadsorption) and their effects on the immunological homeostasis of the maintenance hemodialysis patient. According to the theory, immuno-dysregulation induced by different clinical conditions may lead to peak concentrations of pro- and anti-inflammatory mediators. The impact of a single drug may not be able to cope with the multitude of molecules involved in the process. On the other hand, a non-specific removal of mediators may instead preferentially remove molecules with higher concentration leading to a re-equilibration of the immuno-homeostasis [Figure 1]. We have compared the behavior of β 2M in

Table 2

HA-HD: Indications/benefits.

HA-HD indications	Documented effects Improvement in
Chronic Inflammation	Appetite/nutrition
β 2M accumulation	Muscular strenght
Anorexia, malnutrition	Cognitive function
Uremic pruritus	Pain relief
Uremic symptoms	Sleep quality
Muscular weakness	Blood pressure control
Sleep disorders	Quality of life
Osteo-articular pain	/

β 2M, beta-2 microglobulin; HA-HD, hemoadsorption combined with hemodialysis.




Figure 1. The diagram describes the alternate increase in concentration of pro-inflammatory and anti-inflammatory mediators in patients undergoing maintenance hemodialysis. This phenomenon, induced by uremic toxins not adequately cleared by current dialysis techniques, may be responsible for a continuous activation of a smoldering subclinical inflammation and immunological dysfunction, with the consequence of accelerated atherosclerosis and increased cardiovascular risk on one side, and the high incidence of infection and sepsis on the other side. The application of HA-HD may contribute to eliminate the peaks of different mediators together with the causative mechanism induced by uremic toxins, restoring a more physiological level of immune-homeostasis. CV, cardiovascular; CVD, cardiovascular disease; CRP, C-reactive protein; IL, interleukins; HA-HD, hemoadsorption combined with hemodialysis; CARS, compensatory anti-inflammatory response syndrome; SIRS, systemic inflammatory response syndrome.

a single session of HA-HD with a single session of HD and HDF calculating single and double pool kinetics [Figure 2]. HA-HD appears to be more effective achieving lower concentrations of $\beta 2M$ at the end of a four-hour session. Considering a volume of distribution of 16%–18% of the body weight, a post-dialytic rebound in plasma is expected [Figure 2 left panel]. Nevertheless, In the right panel of Figure 2 we can observe a progressive reduction of pre-dialysis values when the technique is applied in a 3 sessions/week (s/w) regime. This observation is compatible with a progressive reduction of the $\beta 2M$ pool in the distribution volume due to increased removal during HA-HD. Interestingly enough, studying the behavior of $\beta 2M$ over three months with a progressive reduction of the frequency of application of the HA 130 cartridge from three to one session/week, we can observe a reduction of the time average concentration (TAC) with a maintenance of the lower concentration even with one single

session per week of HA-HD [Figure 3]. Considering that $\beta 2M$ concentration is dependent on the balance between removal and generation in a stable distribution volume condition, we must assume that after the attack (3 s/w) and the stabilization phase (1 s/w), one single session of HA-HD plus 2 s/w or regular high flux dialysis or HDF, allows to maintain permanent lower concentrations of $\beta 2M$ in comparison with the standard treatment. This phenomenon may be explained by a concomitant reduction in generation as hypothesized in Figure 4. In fact, while the insufficient clearance and consequent retention and accumulation of uremic toxins may enhance the inflammatory pattern of the organism and the increased generation of $\beta 2M$, the improved clearance of $\beta 2M$ together with the removal of middle-to-large molecules involved in inflammation, may contribute to ameliorate the inflammatory status of the patient, and reduce the generation of $\beta 2M$ [Figure 4].

beta-2 microglobulin kinetics




Figure 2. Behavior of $\beta 2M$ concentrations in a single session of HA-HD, and HFD or HDF. Different lines for each technique describe single and double pool kinetics considering a distribution volume for $\beta 2M$ of 16%–18% of body weight. The number 0 describes progressive accumulation in the absence of any blood purification technique and allows to estimate the generation rate (values integrated from current and previous observations.^[29–36] $\beta 2M$, beta-2 microglobulin; HDF, hemodiafiltration; HFD, high flux hemodialysis; HA-HD, hemoadsorption combined with hemodialysis; s/w, sessions/week.

beta-2 microglobulin kinetics




Figure 3. Kinetic calculation of time average concentration of $\beta 2M$ in a progression of regime adaptation from 3 to 1 s/w of HA-HD. Maintenance values with 1 s/w regime are derived from published data.^[29–36] $\beta 2M$, beta-2 microglobulin; PTH, parathyroid hormone; CRP, c-reactive protein; HMGB-1, high mobility group box 1 protein; Hb, hemoglobin; Epo, erythropoietin; HA-HD, hemoadsorption combined with hemodialysis; s/w, sessions/week. TAC, time average concentration.

beta-2 microglobulin kinetics

IMH: Inflammation Mitigation Hypothesis




Figure 4. The inflammation mitigation hypothesis is graphically depicted. In the left panel the insufficient removal of uremic toxins and DAMPS leads to accumulation of uremic toxins and produce a smoldering inflammatory pattern that enhances β 2M generation. The consequence is a progressive increase of β 2M in plasma with the well-known clinical consequences. In the right panel a different situation is described. The enhanced clearance of toxins and mediators leads to an increased elimination of β 2M together with a reduction of the inflammation, responsible for increased β 2M generation. The observed effect is a reduction of the plasma levels of β 2M and a lower rate of complication as described in published data.^[29,30] β 2M, beta-2 microglobulin; HDF, hemodiafiltration; DAMPS, damage-associated molecular patterns. HA-HD, hemoadsorption combined with hemodialysis.

CONCLUSIONS

HA-HD appears to be a reliable technique to improve uremic symptoms and to correct the imbalance of the immuno-response in chronic maintenance dialysis patients. In the single session the reduction ratio for β 2M appears superior to other techniques such as high-flux hemodialysis (HFD) or hemodiafiltration (HDF). In the thrice weekly regime, the TAC of β 2M results lower than in HFD and HDF. In the long term, a lower concentration of β 2M seems to be maintained even with a 1 s/w regime. Considering the parallel reduction of inflammatory parameters, typically observed in HA-HD [Figure 3], we could hypothesize that the enhanced removal of uremic toxins and chemical mediators leads to a mitigation of the systemic inflammation with a progressive reduction in the generation of β 2M. Thus, even in presence of 1 s/w of HA-HD and two regular HD or HDF s/w in the maintenance phase, the plasma levels of β 2M remain constantly low due to the lower generation induced by a reduction of the systemic inflammation. This IMH supports the prescription of HA-HD 1 s/w, possibly after a month of 3 s/w regime in those patients where specific symptoms and biochemical parameters suggest inadequate correction of the uremic syndrome. The hypothesis needs to be tested in the real-world scenario and in a wide spectrum of patients, however the basis and rationale for the clinical application of HA-HD remain and may be the beginning of a new era of kinetic studies in maintenance hemodialysis patients with symptoms and complications.

Financial support and sponsorship

This work received no funding.

Authors contribution

All authors contributed to the discussion, preparation, and the content of the manuscript.

Ethics approval and consent to participate

Not applicable.

Conflicts of interest

Claudio Ronco has been advisor or member of the speaker bureau or received honoraria for presentations in the last 3 years from the following companies: Asahi medical, Aferetica, Baxter, Biomerieux, B. Braun, Cytosorbents, Fresenius medical care, Medtronic, Jaftron Medical, ESTOR, Nipro, Medica, GE. All other authors declared no conflicts of interest.

Data availability statement

No additional data.

REFERENCES

1. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. *Chest*. 1993;103(2):565–575.
2. Pinsky MR. Sepsis: a pro- and anti-inflammatory disequilibrium syndrome. *Contrib Nephrol*. 2001;(132):354–166.
3. Adrie C, Pinsky MR. The inflammatory balance in human sepsis. *Intensive Care Med*. 2000;26(4):364–375.
4. Cobb DA, Lee DW. Cytokine Release Syndrome Biology and Management. *Cancer J*. 2021;27(2):119–125.
5. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. *Biol Blood Marrow Transplant*.

- 2019;25(4):e123–e127.
6. Athale J, Busch LM, O'Grady NP. Cytokine Release Syndrome and Sepsis: Analogous Clinical Syndromes with Distinct Causes and Challenges in Management. *Infect Dis Clin North Am.* 2022;36(4):735–748.
 7. García Roche A, Díaz Lagares C, Élez E, Ferrer Roca R. Cytokine release syndrome. Reviewing a new entity in the intensive care unit. *Med Intensiva (Engl Ed).* 2019;43(8):480–488.
 8. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney Int.* 1999;55(2):648–658.
 9. Cozzolino M, Ciceri P, Ronco C. "Inflammasome" Activity in Dialysis Patients: The Need to Go beyond Membrane Separation Mechanisms. *Blood Purif.* 2022;5:2.
 10. Gabriela Cobo, Bengt Lindholm, Peter Stenvinkel. Chronic inflammation in end-stage renal disease and dialysis. *Nephrol Dial Transplant.* 2018;33(suppl_3):iii35–iii40.
 11. Kuhlmann MK, Levin NW. Interaction between nutrition and inflammation in hemodialysis patients. *Contrib Nephrol.* 2005;149:200–207.
 12. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. *Am J Kidney Dis.* 1998;32:107–114.
 13. Cazzavillan S, Ratanarat R, Segala C, et al. Inflammation and subclinical infection in chronic kidney disease: a molecular approach. *Blood Purif.* 2007;25(1):69–76.
 14. Zoccali C, Mallamaci F, Adamczak M, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. *Cardiovasc Res.* 2023;119(11):2017–2032.
 15. Eleftheriadis T, Pissas G, Antoniadis G, Liakopoulos V, Stefanidis I. Damage-associated molecular patterns derived from mitochondria may contribute to the hemodialysis-associated inflammation. *Int Urol Nephrol.* 2014;46(1):107–112.
 16. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. *Ann Intern Med.* 1993;119(8):771–778.
 17. Jankowska M, Cobo G, Lindholm B, Stenvinkel P. Inflammation and Protein-Energy Wasting in the Uremic Milieu. *Contrib Nephrol.* 2017;191:58–71.
 18. Kaysen GA. Role of inflammation and its treatment in ESRD patients. *Blood Purif.* 2002;20(1):70–80.
 19. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. *Nat Rev Immunol.* 2013;13(12):862–874.
 20. Ronco C, Levin NW. End-stage renal disease: a slowly progressive systemic inflammatory response syndrome. *Contrib Nephrol.* 2002;137:379–185.
 21. Kashani K, Cozzolino MG, Massy ZA, et al. Proposal for a New Classification of Solutes of Interest in Uremia and Hemodialysis. *Blood Purif.* 2023;52(3):233–241.
 22. Rosner MH, Reis T, Husain-Syed F, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. *Clin J Am Soc Nephrol.* 2021;16(12):1918–1928.
 23. Ronco C. Hemodiafiltration: Technical and Clinical Issues. *Blood Purif.* 2015;40 (Suppl) 1:2–11.
 24. Ronco C. The Rise of Expanded Hemodialysis. *Blood Purif.* 2017;44(2):I–VIII.
 25. Ronco C, Bellomo R. History and Development of Sorbents and Requirements for Sorbent Materials. *Contrib Nephrol.* 2023;200:2–7.
 26. Pomarè Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and Cytotoxic Evaluation of New Sorbent Cartridges for Blood Hemoperfusion. *Blood Purif.* 2018;46(3):187–195.
 27. Clark WR, Ferrari F, La Manna G, Ronco C. Extracorporeal Sorbent Technologies: Basic Concepts and Clinical Application. *Contrib Nephrol.* 2017;190:43–57.
 28. Kellum JA. Immunomodulation in sepsis: the role of hemofiltration. *Minerva Anesthesiol.* 1999;65(6):410–418.
 29. Zhao D, Wang Y, Wang Y, et al. Randomized Control Study on Hemoperfusion Combined with Hemodialysis versus Standard Hemodialysis: Effects on Middle-Molecular-Weight Toxins and Uremic Pruritus. *Blood Purif.* 2022;11:1–11.
 30. Cheng W, Luo Y, Wang H, et al. Survival Outcomes of Hemoperfusion and Hemodialysis versus Hemodialysis in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis. *Blood Purif.* 2022;51(3):213–225.
 31. Ronco C. Combined Hemoperfusion-Hemodialysis in End-Stage Renal Disease Patients. *Contrib Nephrol.* 2023;200:118–122.
 32. Ronco C, Heifetz A, Fox K, et al. Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. *Int J Artif Organs.* 1997;20(3):136–43.
 33. Tattersall J. Clearance of beta-2-microglobulin and middle molecules in haemodiafiltration. *Contrib Nephrol.* 2007;158:201–209.
 34. Roumelioti ME, Trietley G, Nolin TD, et al. Beta-2 microglobulin clearance in high-flux dialysis and convective dialysis modalities: a meta-analysis of published studies. *Nephrol Dial Transplant.* 2018;33(6):1025–1039.
 35. Maeda K, Shinzato T, Ota T, et al. Beta-2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. *Nephron.* 1990;56(2):118–125.
 36. Brunati CCM, Gervasi F, Cabibbe M, et al. Single Session and Weekly Beta 2-Microglobulin Removal with Different Dialytic Procedures: Comparison between High-Flux Standard Bicarbonate Hemodialysis, Post-Dilution Hemodiafiltration, Short Frequent Hemodialysis with NxStage Technology and Automated Peritoneal Dialysis. *Blood Purif.* 2019;48(1):86–96.
 37. Ronco C, Samoni S, Bellomo R. Hemoperfusion and Immunomodulation. *Contrib Nephrol.* 2023;200:142–148.
 38. Ronco C, Bonello M, Bordoni V, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. *Blood Purif.* 2004;22(1):164–174.
 39. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. *Artif Organs.* 2003;27(9):792–801.

How to cite: Brendolan A, Lorenzin A, De Cal M, Virzi MG, Cantaluppi V, Marengo M, Lentini P, Ronco C. Hemoadsorption Combined with Hemodialysis and the "Inflammation Mitigation Hypothesis". *Integr Med Nephrol Androl.* 2024;11:e00006. doi: 10.1097/IMNA-D-24-00006